Results 71 to 80 of about 130,251 (209)

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance

Nature Communications, 2019
Colorectal cancer cells can acquire resistance to MEK inhibition due to BRAF or KRAS amplification. Here, the authors show that while MEK inhibitor withdrawal in BRAF mutant cells restores sensitivity to the inhibitor through the loss of BRAF ...
Matthew J. Sale, Kathryn Balmanno, Jayeta Saxena, Eiko Ozono, Katarzyna Wojdyla, Rebecca E. McIntyre, Rebecca Gilley, Anna Woroniuk, Karen D. Howarth, Gareth Hughes, Jonathan R. Dry, Mark J. Arends, Pilar Caro, David Oxley, Susan Ashton, David J. Adams, Julio Saez-Rodriguez, Paul D. Smith, Simon J. Cook   +18 more
doaj   +1 more source

BRAF inhibitor and hairy cell leukemia-related transient acantholytic dermatosis [PDF]

, 2020
Grover disease (GD) is an acquired, nonfamilial, nonimmune mediated, transient or persistent acantholytic dermatosis. Herein, we present a 72-year-old man who had clinical and histopathologic findings of GD following two weeks of treatment with ...
Durkin, John R, Elwood, Hillary, Singh, Amy Garcia, Tchanque-Fossuo, Catherine N   +3 more
core  

Erythropoietin-induced serine 727 phosphorylation of STAT3 in erythroid cells is mediated by a MEK-, ERK-, and MSK1-dependent pathway [PDF]

, 2003
Objective. Erythropoietin (EPO) is a key regulator of erythropoiesis, playing a role in both the proliferation and differentiation of erythroid cells.
Bieber, Boer, Chung, Decker, Gabrilove, Gonzalez, Goodnough, Gotoh, Haq, Jain, Jain, Jonk, Kaptein, Kirito, Kirito, Kirito, Lim, Millot, Miyazaki, Mulcahy, Ng, Schuringa, Schuringa, Schuringa, Smithgall, Socolovsky, Teglund, Tilbrook, Turkson, Watowich, Wen, Wen, Woetmann, Yokogami, Youssoufian, Yu, Zhang   +36 more
core   +1 more source

New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy [PDF]

, 2014
Development of selective inhibitors of BRAF has improved the survival of patients with BRAF-mutant melanoma. The progression-free survival after treatment with a BRAF inhibitor is modest, however, and BRAF inhibitors induce cutaneous toxicity, likely due
Luke, Jason J, Ott, Patrick A
core   +1 more source

Simulating BRAFV600E-MEK-ERK signalling dynamics in response to vertical inhibition treatment strategies

npj Systems Biology and Applications
In vertical inhibition treatment strategies, multiple components of an intracellular pathway are simultaneously inhibited. Vertical inhibition of the BRAFV600E–MEK-ERK signalling pathway is a standard of care for treating BRAFV600E-mutated melanoma where
Alice De Carli, Yury Kapelyukh, Jochen Kursawe, Mark A. J. Chaplain, C. Roland Wolf, Sara Hamis   +5 more
doaj   +1 more source

Anti-Inflammatory Properties of Chemical Probes in Human Whole Blood: Focus on Prostaglandin E2 Production

Frontiers in Pharmacology, 2020
We screened 57 chemical probes, high-quality tool compounds, and relevant clinically used drugs to investigate their effect on pro-inflammatory prostaglandin E2 (PGE2) production and interleukin-8 (IL-8) secretion in human whole blood.
Filip Bergqvist, Filip Bergqvist, Yvonne Sundström, Yvonne Sundström, Ming-Mei Shang, Ming-Mei Shang, Iva Gunnarsson, Ingrid E. Lundberg, Michael Sundström, Michael Sundström, Per-Johan Jakobsson, Per-Johan Jakobsson, Louise Berg, Louise Berg   +13 more
doaj   +1 more source

Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. [PDF]

, 2017
BackgroundMetastatic melanoma is an aggressive form of skin cancer with a high mortality rate and the fastest growing global incidence rate of all malignancies.
Ahuja, Amit, Chen, Lei, Daud, Adil, Gill, Japinder, Kamra, Sheily   +4 more
core   +2 more sources

Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro

BMC Cancer, 2018
Background The phosphoinositide-3-kinase (PI3K) pathway is the most commonly activated pathway in cancers due to mutations at multiple nodes and loss of PTEN.
Ozlem Aslan, Mattia Cremona, Clare Morgan, Lydia W. Cheung, Gordon B. Mills, Bryan T. Hennessy   +5 more
doaj   +1 more source

Characterizing genomic alterations in cancer by complementary functional associations. [PDF]

, 2016
Systematic efforts to sequence the cancer genome have identified large numbers of mutations and copy number alterations in human cancers. However, elucidating the functional consequences of these variants, and their interactions to drive or maintain ...
A Azzalini, A Kraskov, A Kraskov, A Singh, A Young, AA Margolin, AJ Butte, Amir Reza Alizad-Rahvar, Andrew Aguirre, Arthur Liberzon, Aviad Tsherniak, B Luo, Barbara A Weir, C Ding, C Scholl, CA Miller, CD Correa, Chet Birger, Chiara Romualdi, CJ Vaske, Cory M Johannessen, D Feng, D Guardavaccaro, D Malhotra, D Nijhawan, D Pandey, DA Barbie, Daniel DiCara, David A Barbie, David J Konieczkowski, DD Shao, Diane D Shao, DP Hollern, DP Minde, DV Foster, EH Linfoot, Eliezer M Van Allen, F Vandin, F Vandin, Francisca Vazquez, G Ciriello, GA Darbellay, Gabriela Alexe, Gabriele Sales, Gad Getz, GM DeNicola, H Joe, H Peng, H Zou, Heidi Greulich, HW Cheung, J Barretina, J Lin, J Rosenbluh, JA McCubrey, Jesse S Boehm, Jill P Mesirov, JN Weinstein, Jong Wook Kim, Joseph Rosenbluh, JP Brunet, JS Boehm, L Chin, L Chin, L Waldron, Levi A Garraway, LM Solis, M Meyerson, Mahmoud Ghandi, Masoud Ardakani, MB Raeder, MD Leiserson, ME Abazeed, Michael Noble, Mohamed E Abazeed, MS Lawrence, MS Lawrence, Olga B Botvinnik, Omar Abudayyeh, P Tamayo, Pablo Tamayo, Peter S Hammerman, R Beroukhim, R Firestein, R Steuer, Rameen Beroukhim, S Pendyala, S Sheather, SS Brar, T Valenta, Travis I Zack, William C Hahn, Y Gu, Yashaswi Shrestha   +93 more
core   +1 more source

MTOR cross-talk in cancer and potential for combination therapy [PDF]

, 2018
The mammalian Target of Rapamycin (mTOR) pathway plays an essential role in sensing and integrating a variety of exogenous cues to regulate cellular growth and metabolism, in both physiological and pathological conditions.
Bazzichetto, C., Bria, E., Ciuffreda, L., Cognetti, F., Conciatori, F., Falcone, I., Milella, M, Pilotto, S.   +7 more
core   +3 more sources